Sanofi/Genzyme And Isis Submit Kynamro For Lowering Cholesterol
This article was originally published in The Pink Sheet Daily
Executive Summary
It’s been a long haul, but Sanofi’s Genzyme business unit and Isis have submitted their NDA for a drug that helps lower cholesterol levels in high-risk patients with a rare genetic cardiovascular disease that doesn’t respond well to statins.